Online citations, reference lists, and bibliographies.

The Effects Of Risedronate Administered In Combination With A Proton Pump Inhibitor For The Treatment Of Osteoporosis

S. Itoh, Yohichi Sekino, K. Shinomiya, S. Takeda
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
This study was performed to investigate the effects of the co-administration of proton pump inhibitor (PPI) on the efficacy of bisphosphonate (BP) treatment for osteoporosis. A total of 180 women with low bone mineral density were randomly divided into four groups, one in which sodium risedronate was administered with sodium rabeprazole and one in which only risedronate was administered (BP + PPI and BP groups, respectively). The biomarkers were measured at the baseline and every 3 months, inlcuding: N-terminal telopeptide of type I collagen corrected for creatinine, bone-specific alkaline phosphatase (BAP), parathyroid hormone, bone mineral density (BMD) of the lumbar spine and physical parameters evaluated according to the SF-36v2™ Health Survey. Statistical comparisons of these parameters were performed after 9 months. Data were available for a total of 137 patients (62 in the BP group and 75 in the BP + PPI group). The Δ % value of increase in BMD and improvement of physical functioning in the BP + PPI group were significantly larger, and its decrease in BAP in the BP + PPI group was significantly smaller than that in the BP group. It is expected that risedronate administration in combination with a PPI may be more effective not only for treating osteoporosis but also improving physical fitness than treatment with risedronate alone.
This paper references
10.1016/S0140-6736(96)07088-2
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
D. Black (1996)
10.1001/archinternmed.2011.20
Proton pump inhibitor use and the antifracture efficacy of alendronate.
B. Abrahamsen (2011)
A new probable increasing cause of esophageal ulceration: alendronate.
R. Colina (1997)
10.4065/77.3.262
Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials.
H. Taggart (2002)
10.1007/s001980050010
Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis
J. Reginster (2000)
10.1359/JBMR.050610
Multi-detector row CT imaging of vertebral microstructure for evaluation of fracture risk.
M. Ito (2005)
10.1016/0221-8747(81)90044-8
Diphosphonates: history and mechanisms of action.
H. Fleisch (1981)
10.7326/0003-4819-66-5-917
The absorption of calcium carbonate.
P. Ivanovich (1967)
10.1056/NEJM198708273170903
Gastrointestinal absorption of calcium from milk and calcium salts.
M. Sheikh (1987)
10.1210/JC.2006-1415
Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice.
W. Leslie (2007)
Randomised trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporo
JY Reginster (2000)
10.1001/JAMA.282.14.1344
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
S. Harris (1999)
10.1001/ARCHINTE.160.4.517
Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial.
D. Bauer (2000)
10.1016/0009-9236(95)90245-7
Studies of the oral bioavailability of alendronate
B. Gertz (1995)



This paper is referenced by
10.1007/s41970-019-00095-5
Protonenpumpeninhibitoren und Osteoporoserisiko
Rudolf Wolfgang Gasser (2020)
10.1007/s00774-014-0603-9
Additive effect of elcatonin to risedronate for chronic back pain and quality of life in postmenopausal women with osteoporosis: a randomized controlled trial
Michio Hongo (2014)
10.1155/2014/607145
The Therapeutic Effectiveness of the Coadministration of Weekly Risedronate and Proton Pump Inhibitor in Osteoporosis Treatment
M. Tanaka (2014)
10.3892/br.2016.710
Efficacy of alfacalcidol and alendronate on lumbar bone mineral density in osteoporotic patients using proton pump inhibitors
Daisuke Asaoka (2016)
10.1007/s11938-014-0030-y
Proton Pump Inhibitors and Risk of Bone Fractures
G. Leontiadis (2014)
10.1016/j.bone.2015.08.024
The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study.
Mariëlle M C van der Hoorn (2015)
10.17235/reed.2016.4232/2016
Proton-pump inhibitors adverse effects: a review of the evidence and position statement by the Sociedad Española de Patología Digestiva.
Cristóbal de la Coba Ortiz (2016)
10.17554/ijo.v3i2.1607
Prevalence of Medication-Related Risks for Falls and Osteoporosis at a Hospital Network: A Post-hoc Analysis
Iouri Banakh (2016)
10.1371/journal.pone.0235163
Association between proton pump inhibitor use and risk of fracture: A population-based case-control study
J. Kim (2020)
10.1177/1060028015569594
Risk of Fracture and the Concomitant Use of Bisphosphonates With Osteoporosis-Inducing Medications
A. Nyandege (2015)
10.21037/AMJ.2017.03.04
Proton pump inhibitors in liver cirrhosis: a review of benefits and harms
J. Zhu (2017)
10.1007/s00774-016-0771-x
Efficacy on the risk of vertebral fracture with administration of once-weekly 17.5 mg risedronate in Japanese patients of established osteoporosis with prevalent vertebral fractures: a 156-week longitudinal observational study in daily practice
S. Soen (2016)
10.1007/s00296-018-4142-x
Proton pump inhibitors’ use and risk of hip fracture: a systematic review and meta-analysis
Salman Hussain (2018)
Bone fracture and the interaction between bisphosphonates and proton pump inhibitors: a meta-analysis.
S. Yang (2015)
Semantic Scholar Logo Some data provided by SemanticScholar